Revolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings Results

Revolution Medicines (NASDAQ:RVMD) released its quarterly earnings data on Wednesday. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30), FiscalAI reports. During the same quarter in the previous year, the company earned ($1.12) EPS.

Here are the key takeaways from Revolution Medicines’ conference call:

• daraxonrasib registrational enrollment for RASolute‑302 is complete and an OS event‑driven top‑line readout is expected in the first half of 2026, potentially a major value inflection if positive.
• Zoldonrasib showed encouraging first‑line PDAC combo activity (63% partial response, 95% disease control rate in early data), and the company has initiated RESOLUTE‑305 with RASolute‑309 planned for H2 2026.
• RevMed now has a broad RAS(ON) portfolio — four clinical‑stage inhibitors (daraxonrasib, elironrasib, zoldonrasib, RMC‑5127), a preclinical resistance‑targeting class (RMC‑055) slated for clinical development, and >2,500 patients dosed across programs with eight ongoing/planned Phase III trials.
• Strong liquidity position with $2.03 billion in cash and investments and an innovative Royalty Pharma arrangement providing up to $2 billion in committed capital (first $250M tranche received), reducing near‑term financing risk.
• Spending is ramping materially: Q4 net loss was $364.9M and RevMed guided full‑year 2026 GAAP operating expenses of $1.6–$1.7 billion (including $180–$200M stock‑based comp), reflecting significantly higher R&D and commercial preparation costs that will increase near‑term cash burn.

Revolution Medicines Stock Down 1.5%

Shares of Revolution Medicines stock traded down $1.59 during midday trading on Wednesday, reaching $103.24. 2,763,239 shares of the company’s stock traded hands, compared to its average volume of 1,895,848. The stock has a 50 day moving average of $97.66 and a 200-day moving average of $69.42. Revolution Medicines has a 12 month low of $29.17 and a 12 month high of $124.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Insider Activity at Revolution Medicines

In related news, COO Margaret A. Horn sold 75,000 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at $14,184,289.68. This trade represents a 34.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen Michael Kelsey sold 5,447 shares of Revolution Medicines stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $418,438.54. Following the transaction, the insider owned 278,600 shares of the company’s stock, valued at $21,402,052. The trade was a 1.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 113,792 shares of company stock valued at $10,734,640 in the last three months. Corporate insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds have recently added to or reduced their stakes in RVMD. Nextech Invest Ltd. boosted its stake in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of Revolution Medicines by 6.8% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company’s stock worth $529,227,000 after purchasing an additional 421,112 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Revolution Medicines by 21.7% during the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock valued at $260,298,000 after purchasing an additional 994,538 shares in the last quarter. Deerfield Management Company L.P. lifted its holdings in shares of Revolution Medicines by 7.9% during the third quarter. Deerfield Management Company L.P. now owns 3,650,342 shares of the company’s stock valued at $170,471,000 after purchasing an additional 266,270 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in shares of Revolution Medicines by 197.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,205,555 shares of the company’s stock valued at $175,672,000 after buying an additional 1,463,155 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Needham & Company LLC raised their target price on Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Wolfe Research assumed coverage on shares of Revolution Medicines in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price target for the company. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, HC Wainwright raised their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.